FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC
Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.
Source: onclive.com
Page 23 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
First-Line Treatment for EGFR-Mutant Advanced Lung Cancer
A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.
Source: onclive.com
Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC
The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.
Source: ajmc.com
Tarlatamab Application for SCLC Granted Priority Review by FDA
The treatment developed by Amgen could be the first therapeutic option approved for third-line treatment of advanced small cell lung cancer (SCLC).
Source: ajmc.com
Disease Progression Beyond Frontline KRAS G12C Inhibitors
Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.
Source: onclive.com